Ironwood Pharmaceuticals
IRWD
252 hedge funds and large institutions have $1.77B invested in Ironwood Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 115 increasing their positions, 77 reducing their positions, and 30 closing their positions.
2,144% more call options, than puts
Call options by funds: $718K | Put options by funds: $32K
49% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 77
3% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 30
1% more capital invested
Capital invested by funds: $1.74B → $1.77B (+$23.7M)
0.14% more ownership
Funds ownership: 106.78% → 106.92% (+0.14%)
1% less funds holding
Funds holding: 254 → 252 (-2)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
Man Group
London,
United Kingdom
|
+$32M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$17.1M |
| 3 |
Two Sigma Investments
New York
|
+$12.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.1M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$10.8M |
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$65M |
| 2 |
Jane Street
New York
|
-$18.3M |
| 3 |
RA
Royce & Associates
New York
|
-$17.2M |
| 4 |
Millennium Management
New York
|
-$12.1M |
| 5 |
Morgan Stanley
New York
|
-$7.85M |
IRWD Hedge Fund Activity: Q2 2023 in Review
252 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2023, worth a combined $1.77B — up 1.4% from $1.74B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new IRWD positions and 30 closed out — a net gain of 1 holder — while 115 added to existing stakes and 77 trimmed.
The largest buyer was Man Group, opening a new position worth an estimated $32M. The largest seller was Wellington Management Group, exiting entirely with an estimated $65M sold.
- 252 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2023, down from 254 in Q1 2023.
- Funds reported $1.77B of Ironwood Pharmaceuticals stock for Q2 2023, up 1.4% quarter-over-quarter.
- 31 funds opened new Ironwood Pharmaceuticals positions in Q2 2023 and 30 closed out, a net change of +1 holder.
- The largest Ironwood Pharmaceuticals buyer in Q2 2023 was Man Group, an estimated $32M added.
- The largest Ironwood Pharmaceuticals seller in Q2 2023 was Wellington Management Group, an estimated $65M sold.
Based on aggregated 13F filings for Q2 2023.